Gilead Sciences filed an investigational new drug application Tuesday with the Food and Drug Administration to develop GS 9005, a once-daily protease inhibitor with a drug-resistance profile significantly different from those of existing protease inhibitors, The Wall Street Journal reports. Because of the drug's unique resistance profile, it could be effective for patients who've developed resistance to all other protease medications, company officials say. Gilead plans to begin early human tests later this year.
Search
AI Powered
Human content,
AI powered search.
Latest Stories
Stay up to date with the latest in LGBTQ+ news with The Advocate’s email newsletter, in your inbox five days a week.
@ 2026 Equal Entertainment LLC.
All rights reserved
All rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
The Latest
Support Independent Journalism
LGBTQ+ stories deserve to betold.
Your membership powers The Advocate's original reporting—stories that inform, protect, and celebrate our community.
Become a Member
FOR AS LITTLE AS $5. CANCEL ANYTIME.
More For You
Most Popular
@ 2026 Equal Entertainment LLC. All Rights reserved















